Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab
JEADV Clinical Practice · 12.06.2026
DOI: 10.1002/jvc2.70386 ↗Kurz gefasst
Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 12.06.2026. Verfasst von Sohrab Elahwiesy und 5 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Lichen amyloidosis (LA) is a chronic, pruritic dermatosis with papillary dermal amyloid deposition. Standard therapies often fail, and most reports of dupilumab in LA involve patients with concomitant atopic dermatitis. We report a 32‐year‐old man with refractory, non‐atopic LA who had failed topical corticosteroids, tacrolimus, phototherapy, and acitretin. After 6 months of dupilumab, near‐complete resolution of pruritus and major improvement of skin lesions were achieved. Repeat biopsy demonstrated marked reduction of CD4+ and CD8 + T‐cell infiltrates and complete amyloid clearance, with residual postinflammatory hyperpigmentation. These findings support a direct therapeutic effect of dupilumab in non‐atopic LA and a central role for type 2 inflammation in disease pathogenesis.
Zitieren
APA
Elahwiesy, S., Jochims, F., Kunz, M., Forkel, S., Simon, J., & Klein, B. (2026). Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.70386
Vancouver
Elahwiesy S, Jochims F, Kunz M, Forkel S, Simon J, Klein B. Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab. JEADV Clinical Practice. 2026. doi:10.1002/jvc2.70386
BibTeX
@article{Elahwiesy2026,
author = {Elahwiesy, Sohrab and Jochims, Franziska and Kunz, Manfred and Forkel, Susann and Simon, Jan‐Christoph and Klein, Benjamin},
title = {Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab},
journal = {JEADV Clinical Practice},
year = {2026},
doi = {10.1002/jvc2.70386}
}
EUVIMED